Deferred Revenue

12 Months Ended

Dec. 31, 2016

Deferred Revenue Disclosure [Abstract]

Deferred Revenue

Deferred Revenue

Deferred revenue consists of the following:

	As of December 31,
	2016		2015
Current portion:
Received or receivable from Sanofi (see Note 3a)	$	115,267	$	101,573
Received or receivable from Bayer (see Note 3b)	31,084		24,290
Received or receivable from MTPC (see Note 3c)	9,188		2,352
Received or receivable from Teva (see Note 3d)	43,122		—
Received for technology license agreement (see Note 4)	23,572		23,572
Other	9,431		1,700
	$	231,664	$	153,487
Long-term portion:
Received or receivable from Sanofi (see Note 3a)	$	503,474	$	582,664
Received or receivable from Bayer (see Note 3b)	77,028		31,926
Received or receivable from MTPC (see Note 3c)	45,940		7,059
Received or receivable from Teva (see Note 3d)	194,050		—
Received for technology license agreement (see Note 4)	10,280		33,851
Other	—		9,179
	$	830,772	$	664,679